VYNE Therapeutics

(NASDAQ) VYNE

Current Price$0.67

Market Cap$22.37M

Since IPO (2020)-100%

5 Year-99%

1 Year-30%

1 Month+2%

VYNE Therapeutics Financials at a Glance

Market Cap

$22.37M

Revenue (TTM)

$454.00K

Net Income (TTM)

-$21.46M

EPS (TTM)

-$0.53

P/E Ratio

-1.26

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$0.67

Volume

1,598.556

Open

$0.66

Price

$0.67

Volume

1,598.556

Open

$0.66

Previous Close

$0.67

Daily Range

$0.65 - $0.67

52-Week Range

$0.28 - $1.96

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

1.05 (Average)

Price

$0.67

Volume

1,598.556

Open

$0.66

Previous Close

$0.67

Daily Range

$0.65 - $0.67

52-Week Range

$0.28 - $1.96

Estimated Earnings Date

Aug 13, 2026

VYNE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About VYNE Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

David Domzalski

Website

www.vynetherapeutics.com

Headquarters

Bridgewater, NJ 08807, US

VYNE Financials

Key Financial Metrics (TTM)

Gross Margin

99%

Operating Margin

-54%

Net Income Margin

-47%

Return on Equity

-63%

Return on Capital

-99%

Return on Assets

-83%

Earnings Yield

-79.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.37M

Shares Outstanding

33.35M

Volume

1.60K

Avg. Volume

173.23K

Financials (TTM)

Gross Profit

$547.00K

Operating Income

-$29.75M

EBITDA

-$26.73M

Operating Cash Flow

-$33.12M

Capital Expenditure

$0.00

Free Cash Flow

-$33.12M

Cash & ST Invst.

$29.01M

Total Debt

$0.00

VYNE Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$86.00K

-57.4%

Gross Profit

$80.00K

-60.4%

Gross Margin

93.02%

N/A

Market Cap

$22.37M

N/A

Market Cap/Employee

$1.72M

N/A

Employees

N/A

Net Income

-$3.59M

+58.4%

EBITDA

-$3.81M

+58.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$24.93M

-50.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-82.93%

N/A

Return on Invested Capital

-98.91%

N/A

Free Cash Flow

-$4.08M

+64.4%

Operating Cash Flow

-$4.08M

+64.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

QNRXQuoin Pharmaceuticals, Ltd.

QNRXQuoin Pharmaceuticals, Ltd.$5.04+1.82%

BCLIBrainstorm Cell Therapeutics Inc.

BCLIBrainstorm Cell Therapeutics Inc.$0.78+2.50%

XTLBXTL Biopharmaceuticals Ltd.

XTLBXTL Biopharmaceuticals Ltd.$2.25-2.97%

TCRTAlaunos Therapeutics, Inc.

TCRTAlaunos Therapeutics, Inc.$1.97-1.01%

SNGXSoligenix, Inc.

SNGXSoligenix, Inc.$0.45+5.39%

KTTAPasithea Therapeutics Corp.

KTTAPasithea Therapeutics Corp.$0.57-2.53%

ENSCEnsysce Biosciences, Inc.

ENSCEnsysce Biosciences, Inc.$0.24-3.58%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

DSYBig Tree Cloud

DSYBig Tree Cloud$8.94+3.86%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.58-0.03%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.14+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.32-0.05%

MUMicron Technology

MUMicron Technology$908.61-0.03%

LYGLloyds Banking Group Plc

LYGLloyds Banking Group Plc$5.23-0.02%

KEELKeel Infrastructure

KEELKeel Infrastructure$5.33-0.02%

Questions About VYNE

What is the current price of VYNE Therapeutics?

VYNE Therapeutics is trading at $0.65 per share.

What is the 52-week range for VYNE Therapeutics?

Over the past 52 weeks, VYNE Therapeutics has traded between $0.28 and $1.96.

How much debt does VYNE Therapeutics have?

As of the most recent reporting period, VYNE Therapeutics reported total debt of $0.00.

How much cash does VYNE Therapeutics have on hand?

VYNE Therapeutics reported $24.63M in cash and cash equivalents in its most recent financial results.

What is VYNE Therapeutics’s dividend yield?

VYNE Therapeutics does not currently have a dividend yield.

VYNE Therapeutics

VYNE Therapeutics Financials at a Glance

VYNE News

VYNE Reports Narrower Loss in Fiscal Q2

Why VYNE Therapeutics Stock Is Crashing Today

Can Vyne Therapeutics Stock Keep Soaring?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About VYNE Therapeutics

VYNE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

VYNE Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About VYNE

What is the current price of VYNE Therapeutics?

What is the 52-week range for VYNE Therapeutics?

How much debt does VYNE Therapeutics have?

How much cash does VYNE Therapeutics have on hand?

What is VYNE Therapeutics’s dividend yield?

Premium Investing Services